SCHEMBL19684747

SCHEMBL19684747

CCCCOc1cc(C(N)=O)cc2c1CN(C(=O)OC(C)(C)C)CCO2

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 3/20 0.37
PDE4A P27815 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4C Q08493 2/20 0.37
PIK3CD O00329 1/20 0.36
GPR119 Q8TDV5 4/20 0.35
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
USP30 Q70CQ3 1/20 0.35
NR1H2 P55055 1/20 0.35
CHEK2 O96017 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
CNR2 P34972 1/20 0.34
SIRT3 Q9NTG7 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
PARP14 Q460N5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19684931 0.87 CSF1R (0.39) PDE4DPDE4APDE4BPDE4CPIK3CD
SCHEMBL19684696 0.86 RIPK1 (0.39) PDE4DPDE4APDE4BPDE4CPIK3CD
SCHEMBL19684711 0.86 PIK3CD (0.36) PDE4DPDE4APDE4BPDE4CPIK3CD
SCHEMBL19684712 0.85 SMN1; SMN2 (0.35) PDE4DPDE4APDE4BPDE4CPIK3CD
SCHEMBL19684713 0.85 RIPK1 (0.39) PDE4DPDE4APDE4BPDE4CPIK3CD
SCHEMBL19667665 0.84 HSD17B10 (0.43) SMN1; SMN2USP30KDM4E
SCHEMBL19667604 0.81 USP2 (0.41) PIK3CDGPR119USP2SMN1; SMN2USP30
SCHEMBL19679350 0.81 USP2 (0.41) PIK3CDGPR119USP2SMN1; SMN2USP30
SCHEMBL19667616 0.71 TLR9 (0.41) SMN1; SMN2USP30KDM4E
SCHEMBL19684697 0.70 CCNT1 (0.44) SMN1; SMN2USP30KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP PDE4D 3745/4885PDE4A 3567/4885PDE4B 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.